Ionis: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 9, 2026, Ionis (NASDAQ:IONS) lowered its full-year TRYNGOLZA revenue guidance to approximately $50 million. Commercial execution across new product launches dictates how quickly the business turns its research investments into long-term profits. Three things management said stand out.

1. TRYNGOLZA Revenue Projections Shift Lower as Launch Ramp Slows

TRYNGOLZA treats severe hypertriglyceridemia, a condition marked by elevated blood fat levels that raise acute pancreatitis risks. Doctors must adopt a new treatment approach for patients, which lengthens the time needed to build prescription volumes.

For TRYNGOLZA, we are lowering our 2026 full year revenue guidance to approximately $50 million to reflect a more gradual launch ramp than we had anticipated.
-- Brett Monia, Chief Executive Officer

2. DAWNZERA Sales Momentum Accelerates Across Patient Groups

DAWNZERA treats hereditary angioedema, a rare genetic disorder that causes severe swelling attacks. Repeat prescribing and patient switches from existing preventive options expanded product revenue throughout the period.

These increases were driven primarily by DAWNZERA with product sales of $37 million in the third quarter and $79 million year-to-date. DAWNZERA product sales have increased each quarter since launch, including increasing approximately 40% in the third quarter.
-- Beth Hougen, Chief Financial Officer

3. Pipeline Setbacks Push Cash Flow Breakeven Timeline to 2029

Phase III clinical trials are late-stage studies required to confirm drug efficacy before regulatory approval. Unfavorable trial results in two partnered programs forced management to adjust its financial trajectory, even as it preserves $1.9 billion in cash and investments.

But based on the recent Phase III setbacks and the slower-than-anticipated TRYNGOLZA launch, we do expect the timing to shift from 2028 to 2029. However, our goal is to continue to balance investment and growth with operating discipline and to achieve that sustained positive cash flow.
-- Beth Hougen, Chief Financial Officer

Looking Ahead

Product expansion and mid-stage clinical trials drive the next phase. Patient switches to DAWNZERA, an expanding commercial team, and established partnerships provide structural durability while management monitors prescriber conversion.

Looking ahead, our pipeline offers multiple opportunities to build on our progress.
-- Holly Kordasiewicz, Chief Development Officer

Execution across research programs and commercial launches remains central to long-term value creation.

With a growing portfolio of marketed medicines, a rich pipeline and a team with the capabilities to deliver, we are executing on multiple value drivers for continued growth.
-- Brett Monia, Chief Executive Officer

The Motley Fool has positions in and recommends Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.